
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>Management of Immune Tolerant Chronic Hepatitis B</title>
<style>

<style>
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #f0f4ff, #fafafa);
    color: #2c2c2c;
    padding: 40px;
}

/* Mindmap container */
.mindmap {
    max-width: 900px;
    margin: auto;
    font-size: 16px;
    line-height: 1.7;
}

.mindmap ul {
    margin: 0.5em 0 1em 1em;
    padding-left: 1.5em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #a855f7; /* prettier bullets */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}


/* Collapsible sections */
.mindmap details {
    border-left: 4px solid #8b5cf6;
    background: #ffffff;
    margin: 15px 0;
    padding: 16px 20px;
    border-radius: 16px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.12);
    transition: all 0.3s ease;
    position: relative;
}

/* Hover glow */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.2);
    background: linear-gradient(135deg, #ffffff, #f3f0ff);
}

/* Summary styling */
.mindmap summary {
    cursor: pointer;
    font-size: 1.15em;
    font-weight: 600;
    list-style: none;
    position: relative;
    padding-left: 28px;
    color: #4c1d95;
}

/* Custom arrow */
.mindmap summary::before {
    content: "▶";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Titles */
.mindmap summary strong {
    display: block;
    font-size: 1.3em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Description bullets */
.mindmap ul {
    padding-left: 22px;
    margin-top: 10px;
    margin-bottom: 12px;
}

.mindmap li {
    margin-bottom: 6px;
    font-size: 0.97em;
    color: #444;
    list-style-type: disc;
    position: relative;
    padding-left: 4px;
}

/* Nesting indent style */
.mindmap details > div > details {
    margin-left: 20px;
    border-color: #a855f7;
    background: #f9f5ff;
}

/* Fade-in effect */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* Description box */
.mindmap .desc-box {
    background: #fdfcff;
    border: 1px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 4px 6px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.06);
    transition: background 0.3s ease;
}

.mindmap .desc-box:hover {
    background: #f9f4ff;
}


button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 1em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease;
}
button:hover {
    background-color: #6b21a8;
}


@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}


#level-controls button {
    background-color: rgba(124, 58, 237, 0.7); /* semi-transparent purple */
    color: white;
    border: none;
    padding: 8px 14px;
    margin: 0 6px;
    font-size: 1em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s;
}

#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.85); /* slightly darker on hover */
    transform: scale(1.05);
}

#level-controls {
    position: fixed;
    bottom: 20px;
    left: 50%;
    transform: translateX(-50%);
    background: rgba(124, 58, 237, 0.1);
    padding: 8px 14px;
    border-radius: 12px;
    box-shadow: 0 4px 10px rgba(0, 0, 0, 0.1);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move; /* shows move cursor */
}

</style>




</style>
</head>
<body>
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="setMindmapLevel(1)">Level 1</button>
    <button onclick="setMindmapLevel(2)">Level 2</button>
    <button onclick="setMindmapLevel(3)">Level 3</button>
</div>

<div class="mindmap">

    <div class="mindmap">
        
        <details>
            <summary><strong>Management of Immune Tolerant Chronic Hepatitis B</strong></summary>
            <div>
                <ul><li>Review article on immune-tolerant (IT) phase of chronic hepatitis B (CHB).</li><li>Challenges the notion of IT as a benign phase.</li><li>Discusses controversies and lack of consensus regarding treatment.</li></ul>
                
        <details>
            <summary><strong>Introduction</strong></summary>
            <div>
                <ul><li>CHB: Major global health problem, ≈296 million people affected, ≈1.5 million new infections annually.</li><li>CHB is dynamic, heterogeneous, w/ periods of immune activity &amp; quiescence.</li><li>IT phase: Early decades of life, variable duration, longest in perinatal acquisition.</li></ul>
                
        <details>
            <summary><strong>IT Phase Characteristics</strong></summary>
            <div>
                <ul><li>Absence of liver injury despite high viral replication.</li><li>Assumed lack of immunological recognition &amp; limited host immune response.</li><li>Recent findings: Pro-carcinogenic processes (low-grade inflammation, HBV-DNA integration) may be present.</li></ul>
                
        <details>
            <summary><strong>Controversy</strong></summary>
            <div>
                <ul><li>IT may not be a healthy carrier state.</li><li>Patients could benefit from antiviral therapy.</li><li>Review of literature on IT CHB &amp; pros/cons of treatment.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Clinical Definitions of Immune Tolerant CHB</strong></summary>
            <div>
                <ul><li>Normal serum ALT: Distinctive feature, but &#x27;normal&#x27; ALT debated.</li><li>ALT thresholds vary across international guidelines.</li><li>AASLD adopts lower serum ALT levels.</li></ul>
                
        <details>
            <summary><strong>AASLD Definition</strong></summary>
            <div>
                <ul><li>HBeAg+, HBV-DNA &gt; 10^6 IU/mL, normal ALT (&lt;25 U/L females, &lt;35 U/L males).</li><li>Minimal inflammation &amp; fibrosis on liver histology.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>EASL Definition (2017)</strong></summary>
            <div>
                <ul><li>&#x27;HBeAg positive chronic HBV infection&#x27;.</li><li>HBeAg+, HBV-DNA &gt; 10^7 IU/mL, normal ALT (≈40 IU/L both sexes).</li><li>Minimal/no liver necroinflammation/fibrosis.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>APASL Definition</strong></summary>
            <div>
                <ul><li>HBeAg+, HBV DNA &gt; 10^8 IU/mL, normal ALT (40 IU/L both sexes).</li><li>Minimal to no fibrosis on liver histology.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Table 1: Characteristics of Immune Tolerant CHB in International Guidelines</strong></summary>
            <div>
                <ul><li>Summarizes AASLD, EASL, APASL definitions for IT CHB.</li><li>Key parameters: HBeAg status, HBV DNA level, serum ALT level, fibrosis, necroinflammation.</li></ul>
                
        <details>
            <summary><strong>AASLD</strong></summary>
            <div>
                <ul><li>HBeAg: Positive; HBV DNA: &gt;10^6 IU/ml; Serum ALT: &lt;25 U/L (females), &lt;35 U/L (males); Fibrosis: No-minimal; Necroinflammation: No-minimal</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>EASL</strong></summary>
            <div>
                <ul><li>HBeAg: Positive; HBV DNA: &gt;10^7 IU/ml; Serum ALT: &lt;40 U/L (males &amp; females); Fibrosis: No-minimal; Necroinflammation: No-minimal</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>APASL</strong></summary>
            <div>
                <ul><li>HBeAg: Positive; HBV DNA: &gt;10^8 IU/ml; Serum ALT: &lt;40 U/L (males &amp; females); Fibrosis: No-minimal; Necroinflammation: No-minimal</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Virological and Immunological Parameters of Immune Tolerant CHB</strong></summary>
            <div>
                <ul><li>HBV not directly cytotoxic; host immune response causes hepatocyte injury.</li><li>Immune response drives liver fibrosis &amp; hepatocarcinogenesis.</li><li>IT patients: Minimal/no liver injury due to immune deficiency/tolerance.</li></ul>
                
        <details>
            <summary><strong>CD8+ T Cells</strong></summary>
            <div>
                <ul><li>Crucial for HBV infection resolution via cytokines &amp; eliminating infected hepatocytes.</li><li>Persistent stimulation -&gt; cellular exhaustion (hallmark of chronic infection) -&gt; &#x27;immune tolerance&#x27;.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>T Cell Profile</strong></summary>
            <div>
                <ul><li>Younger IT patients: Partially exhausted T cell profile.</li><li>Adult patients: More fully exhausted T cell profile.</li><li>Suggests earlier antiviral therapy may benefit younger patients.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Dysfunctional B Cells</strong></summary>
            <div>
                <ul><li>Increase in dysfunctional &amp; atypical memory B cells impedes effective host immune response.</li><li>Prolonged inflammatory state accelerates disease progression &amp; promotes fibrosis.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Kennedy et al. Study</strong></summary>
            <div>
                <ul><li>Investigated T-cell cytokine profiles, exhaustion markers, HBV-specific T-cell responses.</li><li>44 patients: 10 IT, 24 IA, 10 inactive.</li><li>IT group: Mean ALT 29 U/L, mean fibrosis F2, mean age 17 years.</li></ul>
                
        <details>
            <summary><strong>Findings</strong></summary>
            <div>
                <ul><li>T-cell profile of IT patients similar to IA.</li><li>Normal ALT ≠ absence of T-cell response.</li><li>Younger patients w/ CHB: Higher frequency of HBV-specific T cells w/ ability to increase &amp; produce cytokines.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Possible Misclassification</strong></summary>
            <div>
                <ul><li>Study may have misclassified early IA patients as IT (ALT up to 39 U/L, mild-moderate fibrosis).</li><li>Findings support evolving view: IT may be immune dysfunction/partial exhaustion, not true tolerance.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Immune Responsiveness Continuum</strong></summary>
            <div>
                <ul><li>IT phase lies on a continuum, not a binary state.</li><li>Ferrando-Martinez et al.: HBV-specific CD8⁺ T cells exhibit impaired cytokine production &amp; limited proliferative capacity.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Imaging Mass Cytometry Study</strong></summary>
            <div>
                <ul><li>Compared immune microenvironment in HBeAg+ IA vs. IT CHB.</li><li>Greater immune activation in IA group.</li><li>Hepatic immune densities correlated w/ serum ALT, hepatic inflammation, fibrosis.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Immune Activation in IT Patients</strong></summary>
            <div>
                <ul><li>Signs of immune activation observed in &gt;50% of CD4+, B, &amp; Kupffer cells.</li><li>Provides evidence against true immunological tolerance.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>HBV DNA Integration</strong></summary>
            <div>
                <ul><li>Viral replication promotes HBV DNA integration into hepatocyte genome.</li><li>Key event driving oncogenesis, even early &amp; w/o necroinflammation.</li><li>Induces genomic instability, alters genetic expression of cellular regulation &amp; proliferation.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Study on HBV DNA Integration</strong></summary>
            <div>
                <ul><li>26 CHB patients (9 IT): Measured HBV-specific T cells, HBV-DNA integration, clonal hepatocyte expansion.</li><li>IT group exhibited notable HBV DNA integration &amp; clonal hepatocyte expansion.</li></ul>
                
        <details>
            <summary><strong>Limitations</strong></summary>
            <div>
                <ul><li>Small sample sizes, heterogeneity in IT definition.</li><li>Results need verification in larger cohort w/ biochemical &amp; clinical features of IT.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Histological Parameters in Immune Tolerant CHB</strong></summary>
            <div>
                <ul><li>IT phase believed devoid of significant histological inflammatory activity &amp; fibrosis.</li><li>Several studies show significant histological lesions may be found in IT patients based on biochemical criteria.</li></ul>
                
        <details>
            <summary><strong>ALT as a Marker</strong></summary>
            <div>
                <ul><li>Clinicians rely on serum ALT to guide treatment decisions.</li><li>Persistently normal ALT believed associated w/ negligible inflammation/fibrosis.</li><li>Repeat liver biopsy rarely performed w/ stable ALT.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>ALT Limitations</strong></summary>
            <div>
                <ul><li>Normal ALT does not always correlate w/ absence of inflammation/fibrosis.</li><li>Evolving definition of &#x27;normal&#x27; ALT: Levels near ULN may reflect ongoing liver inflammation &amp; fibrosis.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>MASLD Confounding Factor</strong></summary>
            <div>
                <ul><li>Growing prevalence of MASLD (formerly NAFLD) can independently elevate ALT.</li><li>Complicates assessment of HBV activity.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Dai et al. Study</strong></summary>
            <div>
                <ul><li>Analyzed 871 CHB patients, 116 in IT phase (HBeAg+, high HBV DNA, normal ALT &lt;40 IU/mL).</li><li>32 (27.6%) had concurrent MASLD.</li></ul>
                
        <details>
            <summary><strong>Findings</strong></summary>
            <div>
                <ul><li>Advanced fibrosis significantly higher in MASLD group vs. non-MASLD (25% vs. 10.7%, P = 0.044).</li><li>Steatosis may increase fibrosis burden even during IT phase.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Huang et al. Study</strong></summary>
            <div>
                <ul><li>Studied 8,718 CHB patients, MASLD in 75.3%.</li><li>Significantly higher median ALT in those w/ MASLD (32 U/L vs. 28 U/L, p &lt; 0.001).</li></ul>
                
        <details>
            <summary><strong>Findings</strong></summary>
            <div>
                <ul><li>ALT emerged as independent predictor of all-cause mortality (HR 1.001 per U/L increase, P = 0.023).</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Li et al. Report</strong></summary>
            <div>
                <ul><li>Patients with high normal ALT level were found to have significant fibrosis on histology compared to those with low normal ALT level.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Hui et al. Study</strong></summary>
            <div>
                <ul><li>Evaluated histological disease progression of 57 patients defined as IT.</li><li>48 remained in IT phase (median ALT 14 U/L) &amp; showed no fibrosis progression after 5 years.</li></ul>
                
        <details>
            <summary><strong>Findings</strong></summary>
            <div>
                <ul><li>9 patients developed elevated ALT (median 38 U/L), likely transitioning to IA phase, &amp; exhibited fibrosis progression on follow-up biopsy.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Wong et al. Study</strong></summary>
            <div>
                <ul><li>Did not observe significant difference in fibrosis progression risk between IT patients w/ low normal ALT (&lt;0.5 × ULN) &amp; high normal ALT (0.5-1xULN).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Dynamic ALT Approach</strong></summary>
            <div>
                <ul><li>Importance of moving beyond static ALT thresholds.</li><li>Emphasize monitoring ALT trends over time, even when values remain within normal range.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Fibrosis Assessment</strong></summary>
            <div>
                <ul><li>In patients w/ IT clinical profile, fibrosis assessment should be considered, especially if consistent increase in serum ALT, even within normal range.</li><li>Routine liver biopsies not feasible for all patients.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Non-invasive Assessments</strong></summary>
            <div>
                <ul><li>Transient elastography preferable due to safety &amp; practicality.</li><li>Limitations in detecting inflammatory activity or early-stage fibrosis should be acknowledged.</li><li>Clinicians may consider most appropriate fibrosis assessment method based on individual clinical context.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Table 2: Histological findings in CHB patients with normal or mildly elevated serum ALT</strong></summary>
            <div>
                <ul><li>Summarizes histological findings from various studies in CHB patients with normal or mildly elevated serum ALT.</li><li>Includes sample size, mean age, mean ALT, median HBV DNA, HBeAg status, and histological findings.</li></ul>
                
        <details>
            <summary><strong>Andreani et. al</strong></summary>
            <div>
                <ul><li>N=40; Mean Age: 29.2; Mean ALT: &lt;35 U/L; Median HBV DNA: 8.6x10^8 IU/mL; HBeAg: Positive; Histological findings: F0: 50%, F1: 50%</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Kumar et. al</strong></summary>
            <div>
                <ul><li>N=73; Mean Age: 27.7; Mean ALT: &lt;40 U/L; Median HBV DNA: 5.23 log copies/mL; HBeAg: Positive; Histological findings: F0: 17.8%, F1: 42.5%, F2: 26%, F3: 11.0%, F4: 2.7%</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Terrault et. al</strong></summary>
            <div>
                <ul><li>N=237; Mean Age: 36; Mean ALT: 66 U/L; Median HBV DNA: 9.5 log10 copies/mL; HBeAg: Positive; Histological findings: F&gt;4: 11% (Ishak score)</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Lai et. al</strong></summary>
            <div>
                <ul><li>N=59; Mean Age: 37; ALT &lt; 25 U/L (N=20), ALT 26-40 U/L (N=39); Median HBV DNA: 6.3 log10 copies/mL; HBeAg: Positive; Histological findings: ALT &lt; 25 U/L: F2: 20%, ALT 26-40 U/L: F2: 35%, F4: 5%</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Park et. al</strong></summary>
            <div>
                <ul><li>N=27; Mean Age: 28.2; Mean ALT: 22 U/L; Median HBV DNA: 9.18 log10 copies/mL; HBeAg: Positive; Histological findings: F0: 25.9%, F1: 55.5%, F2: 14.8%, F3: 3.7%, F4: 0%</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Wang et. al</strong></summary>
            <div>
                <ul><li>N=28; Mean Age: 28; Mean ALT: 30 U/L; Median HBV DNA: 8.5 log10 copies/mL; HBeAg: Positive; Histological findings: F0: 36%, F1: 32%, F2: 32%</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Hui et. al</strong></summary>
            <div>
                <ul><li>N=57; Mean Age: 31; Mean ALT: 30 U/L; Median HBV DNA: 9.81 log10 copies/mL; HBeAg: Positive; Histological findings: F0: 33.3%, F1: 66.6%</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Transitioning from the Immune Tolerant to the Immune Active Phase</strong></summary>
            <div>
                <ul><li>IT patients may undergo &#x27;loss of tolerance&#x27; &amp; transition to immune-active HBeAg+ CHB.</li><li>Characterized by decreased HBV DNA, elevated ALT, significant histological disease activity.</li><li>Mechanism underlying decline in tolerance unknown.</li></ul>
                
        <details>
            <summary><strong>Factors Influencing Transition</strong></summary>
            <div>
                <ul><li>Age, HBV genotype may play a role.</li><li>Changes in serum ALT more likely to reflect onset of transition.</li><li>Likelihood of loss of tolerance increases with age.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Korean Study</strong></summary>
            <div>
                <ul><li>Followed 133 children w/ IT CHB for &gt;10 years.</li><li>Low rate (1.7/100 patient-years) of transition to immune-active phase.</li><li>Rate of transition increased significantly with age.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Feld et al. Study</strong></summary>
            <div>
                <ul><li>Transitioning to immune-active disease relatively common in North American cohort (56%).</li><li>Transition rates significant in younger participants.</li><li>IT patients should be monitored regularly irrespective of age.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Hui et al. Observation</strong></summary>
            <div>
                <ul><li>Higher chance of phase transition to IA disease in IT CHB patients w/ serum ALT levels close to upper normal limit.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Korean &amp; Hong Kong Study</strong></summary>
            <div>
                <ul><li>Included 194 treatment-naïve IT CHB patients.</li><li>Likelihood of phase change higher in patients w/ high normal ALT (20-39 U/L) than those w/ low normal ALT (&lt;20 U/L).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Novel Biomarkers</strong></summary>
            <div>
                <ul><li>Novel biomarkers being evaluated to better identify immune activation &amp; predict phase transition.</li><li>qHBsAg, HBV-RNA, HBcrAg typically high in IT patients.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>HBcrAg</strong></summary>
            <div>
                <ul><li>Includes HBcAg, HBeAg, precore protein (p22cr).</li><li>Correlates w/ intrahepatic cccDNA levels &amp; transcriptional activity.</li><li>Valuable marker for assessing viral replication.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Serum HBV RNA</strong></summary>
            <div>
                <ul><li>Surrogate marker for cccDNA transcriptional activity.</li><li>Elevated levels associated w/ increased risk of transitioning from IT to IA phase.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Predictive Value</strong></summary>
            <div>
                <ul><li>HBcrAg, HBV RNA, qHBsAg, HBV DNA may provide better predictive value for liver inflammation &amp; fibrosis progression than HBV DNA levels alone.</li><li>Enhances risk stratification in IT patients.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>HBV Genotype</strong></summary>
            <div>
                <ul><li>Genotype C: Associated w/ prolonged IT phases &amp; higher risk of HCC.</li><li>Genotype B: Characterized by earlier transition to IA phase.</li><li>Genotype testing may offer clinical utility in identifying patients who would benefit from closer monitoring or earlier treatment.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Approaches to Treatment and Guidance in Chronic Hepatitis B</strong></summary>
            <div>
                <ul><li>Current treatment options: Long-term nucleos(t)ide analogs (NA) &amp; finite pegylated interferon (PEG-IFN).</li><li>Traditional treatment endpoints: Undetectable viral load, HBeAg seroconversion, HBsAg loss.</li><li>Most guidelines recommend against treating IT CHB.</li></ul>
                
        <details>
            <summary><strong>Exceptions for Treatment</strong></summary>
            <div>
                <ul><li>EASL: Individuals &gt;40 years.</li><li>Chinese Society of Hepatology: Those &gt;30 years or w/ family history of HBV-related cirrhosis/HCC.</li><li>Pregnant women in IT phase: Finite-duration antiviral therapy to reduce mother-to-child transmission.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>WHO Guidelines (March 2024)</strong></summary>
            <div>
                <ul><li>More flexible approach to expand therapy in CHB patients.</li><li>Aims to consider additional factors influencing treatment decisions (family history of HCC/cirrhosis).</li><li>Recommends therapy in cases of uncertainty.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>WHO Considerations</strong></summary>
            <div>
                <ul><li>Comorbidities (T2DM, MASLD).</li><li>Limited data on IT patients w/ these conditions.</li><li>Both T2DM &amp; MASLD contribute to liver disease progression.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Table 3: World Health Organization, Guidelines for the prevention, diagnosis, care, and treatment for people with chronic hepatitis B infection March 2024</strong></summary>
            <div>
                <ul><li>Summarizes WHO&#x27;s treatment recommendations for adults and adolescents with CHB.</li><li>Includes criteria based on fibrosis evidence, HBV DNA and ALT levels, and family history/comorbidities.</li></ul>
                
        <details>
            <summary><strong>Treatment Recommendations</strong></summary>
            <div>
                <ul><li>1. Significant fibrosis (≥F2) based on APRI score &gt;0.5 or TE &gt;7 kPa or cirrhosis (F4) based on clinical criteria (or APRI &gt;1 or TE &gt;12.5 kPa) regardless of HBV DNA or ALT.</li><li>2. HBV DNA &gt;2000 IU/mL and ALT above ULN (30 U/L for men and 19 U/L for women). For adolescents, ALT&gt;ULN on at least two occasions in 6-12 months.</li><li>3. Family history of liver cancer or cirrhosis; immune suppression; comorbidities (diabetes or MASLD); regardless of APRI, HBV DNA, or ALT.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Therapeutic Response and Outcomes in Immune Tolerant CHB Patients</strong></summary>
            <div>
                <ul><li>In IT patients receiving NA &amp; PEG-IFN, HBeAg loss rate is very low.</li><li>Complete viral suppression can be challenging, w/ high risk of virological relapse.</li><li>PEG-IFN has low efficacy in IT patients w/ low serum ALT.</li></ul>
                
        <details>
            <summary><strong>Buster et al. Study</strong></summary>
            <div>
                <ul><li>Low ALT levels combined w/ high HBV DNA levels are significant predictors of therapy failure.</li><li>Supports rationale for not treating IT individuals.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Phase 2 Randomized Clinical Trial</strong></summary>
            <div>
                <ul><li>Compared TDF &amp; TDF + Emtricitabine in HBeAg+ CHB patients.</li><li>Included 126 patients w/ high HBV DNA (mean=8.41 log10) &amp; normal ALT.</li><li>Treatment duration: 192 weeks.</li></ul>
                
        <details>
            <summary><strong>Findings</strong></summary>
            <div>
                <ul><li>Proportion achieving HBV DNA &lt;69 IU/ml higher in TDF + Emtricitabine group (76%) than TDF alone (55%).</li><li>Only 5% achieved HBeAg loss &amp; seroconversion.</li><li>No HBsAg loss.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Lok et al. Study</strong></summary>
            <div>
                <ul><li>Combination therapy w/ ETV &amp; TDF showed modest advantage over ETV monotherapy in HBeAg+ patients w/ high baseline HBV DNA.</li><li>80.4% on combination therapy achieved HBV DNA &lt;50 IU/mL at week 96 vs. 69.8% on monotherapy (P &lt; 0.05).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>North American Study</strong></summary>
            <div>
                <ul><li>IT patients received entecavir for 8 weeks followed by peginterferon alfa-2a + entecavir for 40 weeks.</li><li>Only one (4%) patient achieved HBeAg loss.</li><li>None met primary endpoint of HBeAg loss &amp; HBV DNA ≤ 1,000 IU/mL 48 weeks after treatment.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Liu et al. Study</strong></summary>
            <div>
                <ul><li>Followed 171 patients w/ biopsy-proven CHB, including 22 IT patients (ALT &lt; ULN, METAVIR &lt; A2/F2) who received antiviral therapy.</li><li>36% treated with entecavir, 18.2% with Peg-IFN-α-2a, 45.4% with other NAs.</li></ul>
                
        <details>
            <summary><strong>Findings</strong></summary>
            <div>
                <ul><li>In treated IT group, 9.1% experienced HBeAg seroconversion.</li><li>Virological response (HBV DNA &lt; lower limit of quantification) achieved in 18.2%.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Recent Advances</strong></summary>
            <div>
                <ul><li>Novel antiviral strategies (capsid assembly modulators, RNA interference) in combination w/ NA or PEG-IFN.</li><li>Early-phase trials: Combination therapies can enhance viral suppression compared to NA monotherapy.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Impact of Treatment on Hepatocellular Carcinoma Risk in Immune Tolerant Chronic Hepatitis B</strong></summary>
            <div>
                <ul><li>HCC risk in true IT CHB is considered low.</li><li>HBeAg-positivity &amp; high HBV DNA levels are risk factors for HCC development.</li><li>REVEAL-HBV study: Persistent viremia is critical driver of HCC risk.</li></ul>
                
        <details>
            <summary><strong>Kim et al. Study</strong></summary>
            <div>
                <ul><li>Studied HCC risk in 413 treatment-naïve &amp; 1497 treated IA patients.</li><li>Mean ALT 19 U/L, median HBV DNA 8 log10 IU/mL.</li><li>26.2% of IT patients had HBV DNA 4–6 log10 IU/mL.</li></ul>
                
        <details>
            <summary><strong>Findings</strong></summary>
            <div>
                <ul><li>Risk of HCC &amp; death/liver transplantation significantly higher in untreated IT patients than in treated IA group (12.7% vs. 6.1%).</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Hye et al. Study</strong></summary>
            <div>
                <ul><li>Concluded that HCC risk was higher in patients with treated HBeAg-positive CHB compared to IT patients who remained treatment naïve.</li><li>Included 194 treatment-naïve IT CHB patients and 454 treated HBeAg-positive CHB patients.</li></ul>
                
        <details>
            <summary><strong>Findings</strong></summary>
            <div>
                <ul><li>During follow-up (median, 5 years), none of the patients in the IT group developed HCC compared to four (0.9%) patients in the treated HBeAg-positive group.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Meta-Analysis</strong></summary>
            <div>
                <ul><li>Meta-analysis of 13 studies including 11903 patients.</li><li>Incidence rates of HCC &amp; mortality were comparable between treatment-naïve IT CHB patients &amp; treated IA non-cirrhotic HBeAg-positive CHB patients.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Hsu et al. Study</strong></summary>
            <div>
                <ul><li>RNA sequencing of liver biopsies from 119 patients w/ HBV viral loads &gt;2,000 IU/mL &amp; ALT 1-2 x ULN.</li><li>64 treated w/ TDF, 55 received placebo for 3 years.</li><li>Distinct viral integrations significantly reduced in TDF group.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>HCC Surveillance</strong></summary>
            <div>
                <ul><li>HCC surveillance remains critical component of IT patient management.</li><li>Particularly in those w/ additional risk factors (family history, older age).</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Identifying Immune-Tolerant Patients Who Can Benefit from Therapy</strong></summary>
            <div>
                <ul><li>Current guidelines reluctant to treat IT patients.</li><li>IT patients aged &gt; 30 years &amp; those w/ increasing serum ALT levels, even within normal range, are at risk of phase transition.</li><li>Early treatment could reduce risk of significant disease activity, inflammation, &amp; fibrosis progression.</li></ul>
                
        <details>
            <summary><strong>High-Risk IT Patients</strong></summary>
            <div>
                <ul><li>Individuals w/ significant family history of CHB related complications (HCC, cirrhosis, decompensation).</li><li>Patients at risk of virus transmission should be evaluated for treatment.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Patient Discussions</strong></summary>
            <div>
                <ul><li>Engage in transparent discussions w/ patients, weighing advantages &amp; disadvantages of treatment.</li><li>Consider financial strain on patients w/o drug coverage.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Treatment Considerations</strong></summary>
            <div>
                <ul><li>Clinicians should consider comprehensive evaluation of advantages &amp; drawbacks of treatment.</li><li>Consider alternative endpoints to therapy (low viral loads, sustained biochemical &amp; histological normalization).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Treatment Duration</strong></summary>
            <div>
                <ul><li>Treatment should not be discontinued before achieving HBeAg seroconversion.</li><li>Premature cessation may increase risk of adverse outcomes (HBV reactivation, severe flares).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Table 4: The Advantages and Disadvantages of Treating Immune-Tolerant CHB Patients</strong></summary>
            <div>
                <ul><li>Lists the pros and cons of treating IT CHB patients.</li><li>Includes factors related to HCC risk, viral transmission, fibrosis, treatment efficacy, and potential side effects.</li></ul>
                
        <details>
            <summary><strong>Pros</strong></summary>
            <div>
                <ul><li>Earlier reduction in HBV DNA integration, reducing HCC risk. HBV DNA suppression reduces hepatic fibrosis risk. Reduces vertical and horizontal transmission. Alleviates patient anxiety. Enables primary care providers to treat CHB.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Cons</strong></summary>
            <div>
                <ul><li>INF therapy is not effective in IT patients. Difficult to achieve complete viral suppression on NA. Long-term commitment to medication. Risk of HBV flares with discontinuing therapy. Potential drug resistance. Side effects include Nephrotoxicity with TDF-based therapy</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Unresolved Questions and Conclusion</strong></summary>
            <div>
                <ul><li>Important gaps remain in understanding IT phase (disease progression, optimal treatment strategies, long-term impact of early intervention).</li><li>Lack of consensus in literature &amp; among guidelines regarding definition of true IT CHB.</li></ul>
                
        <details>
            <summary><strong>Stringent Definition Needed</strong></summary>
            <div>
                <ul><li>Stringent &amp; uniform definition of IT CHB is essential to facilitate better understanding of this distinctive phase &amp; to determine appropriate timing for intervention.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Future Research</strong></summary>
            <div>
                <ul><li>Long-term randomized controlled trials required to evaluate advantages of early therapy initiation during IT phase to prevent long-term outcomes &amp; CHB-related complications.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Current Recommendations</strong></summary>
            <div>
                <ul><li>Antiviral therapy is currently recommended for a subset of patients with immune-tolerant CHB infection.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Table 5: Unresolved Questions in Immune-Tolerant Chronic Hepatitis B</strong></summary>
            <div>
                <ul><li>Summarizes key unresolved questions regarding the natural history, histological changes, treatment, and cost-benefit analysis of IT CHB.</li></ul>
                
        <details>
            <summary><strong>Natural History</strong></summary>
            <div>
                <ul><li>What is the incidence of phase transition according to age and ALT levels? How does liver fibrosis progress over time in patients who remain in the IT phase? What biomarkers can reliably predict phase transition in IT patients?</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Histological Changes</strong></summary>
            <div>
                <ul><li>What is the true prevalence of significant histological findings in IT patients, and how does it vary across different populations?</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Treatment</strong></summary>
            <div>
                <ul><li>What is the optimal nucleos(t)ide analog regimen for IT patients— monotherapy or combination therapy? How does antiviral therapy influence pro-oncogenic processes such as HBV DNA integration? What is the risk of developing antiviral resistance in IT patients who fail to achieve complete viral suppression? How does early vs delayed treatment affect long-term risks of HCC and fibrosis progression?</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Cost-Benefit Analysis</strong></summary>
            <div>
                <ul><li>What is the cost-effectiveness of treating IT patients, particularly in low-resource settings, and how does it compare with delayed treatment?</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
    </div>
    
</div>


<script>
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');

    // Close all
    allDetails.forEach(detail => detail.removeAttribute('open'));

    // Open based on depth
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') depth++;
            parent = parent.parentElement;
        }
        if (depth < level) detail.setAttribute('open', '');
    });
}

// Automatically open to level 1 on page load
window.addEventListener('DOMContentLoaded', () => {
    setMindmapLevel(1);
});

function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;

    const onMouseDown = (e) => {
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };

    const elementDrag = (e) => {
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none"; // cancel centering transform
        elmnt.style.bottom = "auto"; // cancel fixed bottom
    };

    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };

    onMouseDown(event);
}
</script>


</body>
</html>
